CIRCULATORY EFFECTS OF ORAL AND SUBCUTANEOUS ADMINISTRATION IN NORMAL SUBJECTS OF A NEW BRONCHODILATOR, IBUTEROL, A PRO‐DRUG TO TERBUTALINE